ATE470453T1 - Verfahren zur behandlung von atherosklerose - Google Patents
Verfahren zur behandlung von atheroskleroseInfo
- Publication number
- ATE470453T1 ATE470453T1 AT05735998T AT05735998T ATE470453T1 AT E470453 T1 ATE470453 T1 AT E470453T1 AT 05735998 T AT05735998 T AT 05735998T AT 05735998 T AT05735998 T AT 05735998T AT E470453 T1 ATE470453 T1 AT E470453T1
- Authority
- AT
- Austria
- Prior art keywords
- treating atherosclerosis
- atherosclerosis
- treating
- treatment
- autoimmune diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55994404P | 2004-04-06 | 2004-04-06 | |
| PCT/US2005/011767 WO2005099755A2 (en) | 2004-04-06 | 2005-04-06 | Methods of treating autoimmune and inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE470453T1 true ATE470453T1 (de) | 2010-06-15 |
Family
ID=35150504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05735998T ATE470453T1 (de) | 2004-04-06 | 2005-04-06 | Verfahren zur behandlung von atherosklerose |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050265993A1 (de) |
| EP (1) | EP1737490B1 (de) |
| JP (1) | JP4812748B2 (de) |
| KR (1) | KR20070036035A (de) |
| CN (2) | CN102847149B (de) |
| AT (1) | ATE470453T1 (de) |
| AU (1) | AU2005232653B2 (de) |
| CA (1) | CA2563260C (de) |
| DE (1) | DE602005021766D1 (de) |
| DK (1) | DK1737490T3 (de) |
| EA (1) | EA012725B1 (de) |
| ES (1) | ES2348984T3 (de) |
| IL (2) | IL178478A (de) |
| MX (1) | MXPA06011526A (de) |
| NO (2) | NO340627B1 (de) |
| PT (1) | PT1737490E (de) |
| UA (2) | UA103594C2 (de) |
| WO (1) | WO2005099755A2 (de) |
| ZA (1) | ZA200608884B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4939899B2 (ja) * | 2006-10-30 | 2012-05-30 | オムロンオートモーティブエレクトロニクス株式会社 | 導電端子の溶接方法、および導電端子構造 |
| WO2008119567A2 (en) † | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| JP2013526594A (ja) * | 2010-05-24 | 2013-06-24 | インデナ エッセ ピ ア | 微生物感染の治療に使用するためのタマリンド種子多糖 |
| EP2640750A1 (de) * | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP2015091761A (ja) * | 2012-02-23 | 2015-05-14 | 国立大学法人大阪大学 | 中枢神経の損傷を治療するための組成物およびその利用 |
| US9664690B1 (en) * | 2013-08-28 | 2017-05-30 | The National Institute For Biotechnology I | Molecular diagnostic kits for evaluating stress |
| JP7474702B2 (ja) | 2018-03-28 | 2024-04-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法 |
| EP3866831A4 (de) * | 2018-10-16 | 2022-08-24 | Board of Regents, The University of Texas System | Identifizierung und targeting der pathogenen extrazellulären matrix zur diagnose und behandlung von krebs und anderen krankheiten |
| JP2022512709A (ja) | 2018-10-31 | 2022-02-07 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | 炎症性疾患及び自己免疫疾患を処置する組成物及び方法 |
| US12122850B2 (en) | 2022-03-14 | 2024-10-22 | LamKap Bio gamma AG | Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025477A (en) | 1986-03-31 | 2000-02-15 | Calenoff; Emanuel | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| EP0710116B1 (de) * | 1993-05-13 | 2008-09-03 | Poniard Pharmaceuticals, Inc. | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
| US7041289B1 (en) * | 1997-12-05 | 2006-05-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for treating established spontaneous auto-immune diseases in mammals |
| GB2380127A (en) * | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
| US20030216551A1 (en) * | 2002-03-08 | 2003-11-20 | Diabetogen Biosciences Inc. | Fully human anti-CD3 monoclonal antibodies |
| JP2007538000A (ja) * | 2004-01-08 | 2007-12-27 | リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | 制御性ｔ細胞は自己免疫を抑制する |
-
2005
- 2005-04-06 CN CN201210279646.9A patent/CN102847149B/zh not_active Expired - Lifetime
- 2005-04-06 AU AU2005232653A patent/AU2005232653B2/en not_active Expired
- 2005-04-06 JP JP2007507498A patent/JP4812748B2/ja not_active Expired - Lifetime
- 2005-04-06 US US11/099,716 patent/US20050265993A1/en not_active Abandoned
- 2005-04-06 EA EA200601871A patent/EA012725B1/ru unknown
- 2005-04-06 KR KR1020067022486A patent/KR20070036035A/ko not_active Withdrawn
- 2005-04-06 WO PCT/US2005/011767 patent/WO2005099755A2/en not_active Ceased
- 2005-04-06 UA UAA200907841A patent/UA103594C2/ru unknown
- 2005-04-06 AT AT05735998T patent/ATE470453T1/de active
- 2005-04-06 EP EP05735998A patent/EP1737490B1/de not_active Expired - Lifetime
- 2005-04-06 DK DK05735998.6T patent/DK1737490T3/da active
- 2005-04-06 ES ES05735998T patent/ES2348984T3/es not_active Expired - Lifetime
- 2005-04-06 PT PT05735998T patent/PT1737490E/pt unknown
- 2005-04-06 DE DE602005021766T patent/DE602005021766D1/de not_active Expired - Lifetime
- 2005-04-06 UA UAA200611467A patent/UA89780C2/ru unknown
- 2005-04-06 CN CN2005800181398A patent/CN1972714B/zh not_active Expired - Lifetime
- 2005-04-06 CA CA2563260A patent/CA2563260C/en not_active Expired - Lifetime
- 2005-04-06 MX MXPA06011526A patent/MXPA06011526A/es active IP Right Grant
-
2006
- 2006-10-05 IL IL178478A patent/IL178478A/en unknown
- 2006-10-25 ZA ZA200608884A patent/ZA200608884B/en unknown
- 2006-10-26 NO NO20064896A patent/NO340627B1/no unknown
-
2010
- 2010-11-16 IL IL209338A patent/IL209338A0/en active IP Right Grant
-
2017
- 2017-05-04 NO NO20170737A patent/NO20170737A1/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1737490A2 (de) | 2007-01-03 |
| CA2563260A1 (en) | 2005-10-27 |
| AU2005232653B2 (en) | 2010-12-16 |
| NO20064896L (no) | 2006-11-06 |
| CN102847149B (zh) | 2016-01-20 |
| DK1737490T3 (da) | 2010-10-04 |
| IL178478A (en) | 2010-12-30 |
| WO2005099755A3 (en) | 2006-04-27 |
| EA200601871A1 (ru) | 2007-04-27 |
| PT1737490E (pt) | 2010-08-31 |
| US20050265993A1 (en) | 2005-12-01 |
| ZA200608884B (en) | 2008-06-25 |
| IL209338A0 (en) | 2011-01-31 |
| EP1737490B1 (de) | 2010-06-09 |
| JP4812748B2 (ja) | 2011-11-09 |
| DE602005021766D1 (de) | 2010-07-22 |
| IL178478A0 (en) | 2007-02-11 |
| EA012725B1 (ru) | 2009-12-30 |
| CN1972714B (zh) | 2012-10-03 |
| UA89780C2 (ru) | 2010-03-10 |
| NO340627B1 (no) | 2017-05-15 |
| MXPA06011526A (es) | 2007-03-21 |
| WO2005099755A2 (en) | 2005-10-27 |
| KR20070036035A (ko) | 2007-04-02 |
| ES2348984T3 (es) | 2010-12-21 |
| JP2007532565A (ja) | 2007-11-15 |
| NO20170737A1 (no) | 2006-11-06 |
| CA2563260C (en) | 2013-05-28 |
| CN1972714A (zh) | 2007-05-30 |
| HK1099525A1 (en) | 2007-08-17 |
| UA103594C2 (ru) | 2013-11-11 |
| AU2005232653A1 (en) | 2005-10-27 |
| CN102847149A (zh) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| EP4093355A4 (de) | Systeme und verfahren zur behandlung von hörverlust | |
| EP1816990A4 (de) | Systeme, vorrichtungen und verfahren zur behandlung von bandscheibenerkrankungen | |
| DE602006018583D1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
| ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| EP4415755A4 (de) | Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19 | |
| EP4204443A4 (de) | Verfahren und zusammensetzungen zur behandlung von glioblastom | |
| EP4188368A4 (de) | Zusammensetzungen und verfahren zur behandlung von erkrankungen und störungen | |
| ATE470453T1 (de) | Verfahren zur behandlung von atherosklerose | |
| EP4097236A4 (de) | Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen | |
| EP1948675A4 (de) | Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen | |
| DE602004001134D1 (de) | Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit | |
| EP3945077C0 (de) | Verfahren und system zur behandlung von biofeststoffen | |
| EP4114411A4 (de) | Zusammensetzungen und verfahren zur behandlung von bauchspeicheldrüsenkrebs | |
| EP4034109A4 (de) | Verfahren und zusammensetzung zur behandlung von erkrankungen | |
| EP4395752A4 (de) | Verfahren zur behandlung von cb1-, trpa1- und trpv1-abhängigen erkrankungen | |
| EP1919290A4 (de) | Verfahren und produkte zur behandlung von krankheiten | |
| EP4340897A4 (de) | Verfahren und zusammensetzungen zur behandlung von pankreas- und lebererkrankungen | |
| DE602004010548D1 (de) | Verfahren zur behandlung von tierhäuten | |
| EP4073102A4 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von gehörverlust | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| DE602004011275D1 (de) | Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit | |
| EP4469490A4 (de) | Zusammensetzungen, vorrichtungen und verfahren zur behandlung von zns-erkrankungen | |
| EP4213835A4 (de) | Zusammensetzungen und verfahren zur behandlung von lipidbedingten erkrankungen | |
| ATE410235T1 (de) | Behandlung von ballastwasser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1737490 Country of ref document: EP |